Point of Care Immunoassay Diagnostic Platform

护理点免疫分析诊断平台

• 批准号: 700461
• 金额: $ 2.97万
• 依托单位: BIO ALTERNATIVE MEDICAL DEVICES LIMITED
• 依托单位国家: 英国
• 项目类别: GRD Proof of Market
• 财政年份: 2014
• 资助国家: 英国
• 起止时间: 2014 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=700461
• 关键词: Point; Care; Immunoassay; Diagnostic; Platform

In acute medical situations, where speed of diagnosis is critical, effective near-patient or Pointof-Care (PoC) testing can play a crucial role. The ability to conduct a rapid test in an emergency or critical care setting, where continuous monitoring is required, will significantly accelerate the triage, diagnosis, treatment and disposition of patients. PoC testing can effectively reduce unnecessary hospital admissions and the burden placed on centralisedlaboratories. However, many of the PoC technologies available lack the required sensitivity and accuracy to provide fully quantitative measurements; a pre-requisite now demanded by healthcare professionals of future PoC devices. Bio-Alternative Medical Devices (Bio-AMD) has identified this gap in the market and has devised a PoC platform that will deliver the levelof sensitivity required for significantly more accurate measurements with the precision of gold standard laboratories.

在诊断速度至关重要的急性医疗情况下，有效的近病人或点护理（PoC）检测可以发挥关键作用。在需要持续监测的紧急或重症监护环境中进行快速检测的能力将大大加快对患者的分诊、诊断、治疗和处置。PoC检测可以有效减少不必要的住院和中央实验室的负担。然而，现有的许多PoC技术缺乏提供充分定量测量所需的灵敏度和准确性；这是医疗保健专业人员现在要求的未来PoC设备的先决条件。生物替代医疗设备（Bio-AMD）已经确定了市场上的这一空白，并设计了一个PoC平台，该平台将提供所需的灵敏度水平，以达到金标准实验室的精度，实现更准确的测量。